Lee Chang-Kyun, Kim Hyo-Jong
Department of Internal Medicine, Kyunghee University School of Medicine, Seoul, Korea.
Korean J Gastroenterol. 2007 Jul;50(1):3-8.
Intestinal Behçet's disease (BD) refers to colonic ulcerative lesions documented by objective measures in patients with BD. Although the causes of intestinal BD are unknown, genetic, environmental, and immunological factors have been suggested. Intestinal BD is common in BD patients from Far East, while it is uncommon in those from the Middle East. The reasons for such peculiar geographic distribution in intestinal BD are unknown, but may provide clues for the elucidation of putative etiological agents or genetic factors that might be associated with intestinal BD. Although the treatment of Crohn's disease has improved significantly during past decade, the treatment of intestinal BD is still problematic. Corticosteroids, sulfasalazine, immunomodulators, and colchicines have been used to treat intestinal BD with varying degree of success. Thalidomide and its analogues also appear to be applicable. Monoclonal antibodies to TNF-alpha have recently been focused as a novel therapeutic option for patients with intestinal BD.
肠道白塞病（BD）是指白塞病患者经客观检查证实的结肠溃疡性病变。虽然肠道白塞病的病因尚不清楚，但已有研究表明其与遗传、环境和免疫因素有关。肠道白塞病在来自远东地区的白塞病患者中较为常见，而在中东地区的患者中则不常见。肠道白塞病这种特殊地理分布的原因尚不清楚，但可能为阐明可能与肠道白塞病相关的病因或遗传因素提供线索。尽管在过去十年中克罗恩病的治疗有了显著改善，但肠道白塞病的治疗仍然存在问题。皮质类固醇、柳氮磺胺吡啶、免疫调节剂和秋水仙碱已被用于治疗肠道白塞病，且取得了不同程度的成功。沙利度胺及其类似物似乎也适用。抗TNF-α单克隆抗体最近已成为肠道白塞病患者的一种新型治疗选择。
